Hong Kong and Korean cosmetics leaders through Stock Connect.
Q2 2026 earnings release scheduled for 2026-08-19. Analysts forecast a significant increase in operating profit due to the Eli Lilly deal, forecasted. Medium importance estimated as earnings reports typically drive 5-10% volatility.
Cosmax is scheduled to release its Q2 2026 earnings on August 18, 2026. Analysts forecast consolidated revenue around KRW 738 billion (+18% YoY) and operating profit around KRW 70 billion (+15% YoY). Medium importance is estimated as this growth is expected to cause a 5-10% price impact. This event is scheduled.
Yuhan Corp is scheduled to announce its Q2 2026 earnings results on August 18, 2026, scheduled.
Q2 2026 earnings release scheduled. Analysts forecast revenue and profit growth driven by full plant operation and favorable exchange rates, but also note concerns over a slowdown in new orders and potential labor cost increases. Event is scheduled.
The company issued a shareholder letter on July 13, 2026, to address the stock price decline and reaffirm its commitment to the Osong factory and PT403 pipeline.
Announced presentation of positive meta-analysis results for 'Amoprel' at the ESH 2026 meeting on 2026-07-13. Low importance estimated as academic presentations for existing drugs typically have minor market impact.
On July 10, 2026, the stock price plummeted by the daily limit (-29.94%) following a CEO statement on July 9 clarifying that the joint research with Eli Lilly excludes the drug ingredient Tirzepatide.
Announced that the domestic Phase 2 clinical trial for 'Belvarafenib' is progressing smoothly on 2026-07-10, targeting conditional approval in 2028. Low importance estimated as clinical progress updates usually result in 1-5% price movement.
Received a third Complete Response Letter (CRL) from the U.S. FDA on July 9, 2026, for the New Drug Application (NDA) of its liver cancer therapy, Rivoceranib, due to manufacturing issues, causing a >30% stock price drop.